Anti-CD10 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameAnti-CD10 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital)
Drug Alias NameCAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital)Anti-CD20 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital)Anti-CD22 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsCD22 modulatorsNeprilysin modulators
TargetsB-lymphocyte antigen CD20CD22Neprilysin
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSouthern Medical University Zhujing Hospital
China Registration ClassN/A

Develop Information

Active CompaniesSouthern Medical University Zhujing HospitalSouthern Hospital Of Southern Medical University
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A